Singapore, June 12 -- Japan headquartered medtech firm Olympus Corp. has announced the full market release of its artificial intelligence (AI)-driven emphysema screening program, SeleCT Screening.

The SeleCT Screening AI platform, powered by 4DMedical, helps identify severe emphysema patients who may benefit from a clinically proven and minimally invasive procedure to improve lung function called bronchoscopic lung volume reduction (BLVR).

SeleCT Screening automatically reviews existing chest computed tomography (CT) scans throughout a health system to help identify patients who may benefit from BLVR with endobronchial valves such as the Spiration Valve System. Physicians are notified if a potentially qualified patient is identified so ...